[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 6, 1954


JAMA. 1954;154(6):499-501. doi:10.1001/jama.1954.02940400037009

The time is rapidly approaching when a radioisotope program in the general hospital will be taken as much for granted as any other laboratory service. Its scope will depend on the size of the hospital and the interests of the staff, but we can safely say that it will include thyroid function studies, blood volume determinations, radioactive phosphorus (P32) therapy of leukemia and polycythemia, radioactive gold (Au198) therapy for ascites incident to generalized abdominal or pleural carcinomatosis, and radioactive iodine (I131) therapy for exophthalmic goiter. In addition, the radioisotope program may include localization of brain tumors and liver metastases, determination of extracellular fluid volume, isotope clearance measurements for various tissues, studies of peripheral vascular disease, and various types of therapy. Foreseeing this and also wishing to be among those to derive benefit from any new agency, hospital medical boards and administrators are studying procedures and requirements for

First Page Preview View Large
First page PDF preview
First page PDF preview